• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form D filed by Adagio Therapeutics Inc.

    11/29/22 5:16:38 PM ET
    $ADGI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ADGI alert in real time by email
    SEC FORM D

    The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
    The reader should not assume that the information is accurate and complete.

    UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    FORM D

    Notice of Exempt Offering of Securities

    OMB APPROVAL
    OMB Number: 3235-0076
    Estimated average burden
    hours per response: 4.00

    1. Issuer's Identity

    CIK (Filer ID Number) Previous Names
       None
    Entity Type
    0001832038
    Adagio Therapeutics, Inc.
    X Corporation
       Limited Partnership
       Limited Liability Company
       General Partnership
       Business Trust
       Other (Specify)

    Name of Issuer
    Invivyd, Inc.
    Jurisdiction of Incorporation/Organization
    DELAWARE
    Year of Incorporation/Organization
       Over Five Years Ago
    X Within Last Five Years (Specify Year) 2020
       Yet to Be Formed

    2. Principal Place of Business and Contact Information

    Name of Issuer
    Invivyd, Inc.
    Street Address 1 Street Address 2
    1601 Trapelo Road Suite 178
    City State/Province/Country ZIP/PostalCode Phone Number of Issuer
    Waltham MASSACHUSETTS 02451 (781) 819-0080

    3. Related Persons

    Last Name First Name Middle Name
    Hering David
    Street Address 1 Street Address 2
    1601 Trapelo Road Suite 178
    City State/Province/Country ZIP/PostalCode
    Waltham MASSACHUSETTS 02451
    Relationship: X Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):

    Chief Executive Officer and Director
    Last Name First Name Middle Name
    Driscoll Fred
    Street Address 1 Street Address 2
    1601 Trapelo Road Suite 178
    City State/Province/Country ZIP/PostalCode
    Waltham MASSACHUSETTS 02451
    Relationship: X Executive Officer    Director    Promoter

    Clarification of Response (if Necessary):

    Interim Chief Financial Officer
    Last Name First Name Middle Name
    Andersen Jill
    Street Address 1 Street Address 2
    1601 Trapelo Road Suite 178
    City State/Province/Country ZIP/PostalCode
    Waltham MASSACHUSETTS 02451
    Relationship: X Executive Officer    Director    Promoter

    Clarification of Response (if Necessary):

    Chief Legal Officer and Corporate Secretary
    Last Name First Name Middle Name
    Dabora Rebecca
    Street Address 1 Street Address 2
    1601 Trapelo Road Suite 178
    City State/Province/Country ZIP/PostalCode
    Waltham MASSACHUSETTS 02451
    Relationship: X Executive Officer    Director    Promoter

    Clarification of Response (if Necessary):

    Chief Technology and Manufacturing Officer
    Last Name First Name Middle Name
    Hershberger Ellie
    Street Address 1 Street Address 2
    1601 Trapelo Road Suite 178
    City State/Province/Country ZIP/PostalCode
    Waltham MASSACHUSETTS 02451
    Relationship: X Executive Officer    Director    Promoter

    Clarification of Response (if Necessary):

    Chief Development Officer
    Last Name First Name Middle Name
    Elia Marc
    Street Address 1 Street Address 2
    1601 Trapelo Road Suite 178
    City State/Province/Country ZIP/PostalCode
    Waltham MASSACHUSETTS 02451
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):

    Director, Chair of the Board
    Last Name First Name Middle Name
    Berry Tamsin
    Street Address 1 Street Address 2
    1601 Trapelo Road Suite 178
    City State/Province/Country ZIP/PostalCode
    Waltham MASSACHUSETTS 02451
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Heyman Tom
    Street Address 1 Street Address 2
    1601 Trapelo Road Suite 178
    City State/Province/Country ZIP/PostalCode
    Waltham MASSACHUSETTS 02451
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    McGuire Terry
    Street Address 1 Street Address 2
    1601 Trapelo Road Suite 178
    City State/Province/Country ZIP/PostalCode
    Waltham MASSACHUSETTS 02451
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Meanwell Clive A.
    Street Address 1 Street Address 2
    1601 Trapelo Road Suite 178
    City State/Province/Country ZIP/PostalCode
    Waltham MASSACHUSETTS 02451
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Lindenboom Christine
    Street Address 1 Street Address 2
    1601 Trapelo Road Suite 178
    City State/Province/Country ZIP/PostalCode
    Waltham MASSACHUSETTS 02451
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Wyzga Michael S.
    Street Address 1 Street Address 2
    1601 Trapelo Road Suite 178
    City State/Province/Country ZIP/PostalCode
    Waltham MASSACHUSETTS 02451
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    4. Industry Group

       Agriculture
    Banking & Financial Services
       Commercial Banking
       Insurance
       Investing
       Investment Banking
       Pooled Investment Fund
    Is the issuer registered as
    an investment company under
    the Investment Company
    Act of 1940?
       Yes    No
       Other Banking & Financial Services
       Business Services
    Energy
       Coal Mining
       Electric Utilities
       Energy Conservation
       Environmental Services
       Oil & Gas
       Other Energy
    Health Care
    X Biotechnology
       Health Insurance
       Hospitals & Physicians
       Pharmaceuticals
       Other Health Care
       Manufacturing
    Real Estate
       Commercial
       Construction
       REITS & Finance
       Residential
       Other Real Estate
      
    Retailing
      
    Restaurants
    Technology
       Computers
       Telecommunications
       Other Technology
    Travel
       Airlines & Airports
       Lodging & Conventions
       Tourism & Travel Services
       Other Travel
      
    Other

    5. Issuer Size

    Revenue Range OR Aggregate Net Asset Value Range
       No Revenues    No Aggregate Net Asset Value
       $1 - $1,000,000    $1 - $5,000,000
       $1,000,001 - $5,000,000    $5,000,001 - $25,000,000
       $5,000,001 - $25,000,000    $25,000,001 - $50,000,000
       $25,000,001 - $100,000,000    $50,000,001 - $100,000,000
       Over $100,000,000    Over $100,000,000
    X Decline to Disclose    Decline to Disclose
       Not Applicable    Not Applicable

    6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)

       Rule 504(b)(1) (not (i), (ii) or (iii))
       Rule 504 (b)(1)(i)
       Rule 504 (b)(1)(ii)
       Rule 504 (b)(1)(iii)
    X Rule 506(b)
       Rule 506(c)
       Securities Act Section 4(a)(5)
       Investment Company Act Section 3(c)
       Section 3(c)(1)    Section 3(c)(9)  
       Section 3(c)(2)    Section 3(c)(10)
       Section 3(c)(3)    Section 3(c)(11)
       Section 3(c)(4)    Section 3(c)(12)
       Section 3(c)(5)    Section 3(c)(13)
       Section 3(c)(6)    Section 3(c)(14)
       Section 3(c)(7)

    7. Type of Filing

    X New Notice Date of First Sale 2022-11-15    First Sale Yet to Occur
       Amendment

    8. Duration of Offering

    Does the Issuer intend this offering to last more than one year?
       Yes X No

    9. Type(s) of Securities Offered (select all that apply)

    X Equity    Pooled Investment Fund Interests
       Debt    Tenant-in-Common Securities
    X Option, Warrant or Other Right to Acquire Another Security    Mineral Property Securities
    X Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security    Other (describe)

    10. Business Combination Transaction

    Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer?
       Yes X No

    Clarification of Response (if Necessary):

    11. Minimum Investment

    Minimum investment accepted from any outside investor $0 USD

    12. Sales Compensation

    Recipient
    Recipient CRD Number X None
    (Associated) Broker or Dealer X None
    (Associated) Broker or Dealer CRD Number X None
    Street Address 1 Street Address 2
    City State/Province/Country ZIP/Postal Code
    State(s) of Solicitation (select all that apply)
    Check “All States” or check individual States
       All States
       Foreign/non-US

    13. Offering and Sales Amounts

    Total Offering Amount $23,749,998 USD
    or    Indefinite
    Total Amount Sold $23,749,998 USD
    Total Remaining to be Sold $0 USD
    or    Indefinite

    Clarification of Response (if Necessary):

    See Form 8-K filed by Issuer on 11-17-22 for more details. The Issuer issued a warrant to purchase up to an aggregate of 6,824,712 common shares at an exercise price of $3.48 per share, which may vest in up to three separate tranches.

    14. Investors

      
    Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, and enter the number of such non-accredited investors who already have invested in the offering.
    Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:
    1

    15. Sales Commissions & Finder's Fees Expenses

    Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

    Sales Commissions $0 USD
       Estimate
    Finders' Fees $0 USD
       Estimate

    Clarification of Response (if Necessary):

    16. Use of Proceeds

    Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

    $0 USD
       Estimate

    Clarification of Response (if Necessary):

    Signature and Submission

    Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

    Terms of Submission

    In submitting this notice, each issuer named above is:
    • Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.*
    • Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of:  (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
    • Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Rule 504 or Rule 506 for one of the reasons stated in Rule 504(b)(3) or Rule 506(d).

    Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

    For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

    Issuer Signature Name of Signer Title Date
    Invivyd, Inc. /s/ Jill Andersen Jill Andersen Chief Legal Officer and Corporate Secretary 2022-11-29

    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

    * This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.


    Get the next $ADGI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ADGI

    DatePrice TargetRatingAnalyst
    1/6/2022$11.00 → $6.00Equal-Weight → Underweight
    Morgan Stanley
    1/6/2022Overweight → Underweight
    Morgan Stanley
    12/22/2021$46.00 → $10.00Buy → Hold
    Jefferies
    12/15/2021$49.00 → $11.00Overweight → Equal-Weight
    Morgan Stanley
    12/15/2021Buy → Neutral
    Guggenheim
    12/15/2021$50.00 → $9.00Buy → Hold
    Stifel
    11/29/2021$49.00Equal-Weight → Overweight
    Morgan Stanley
    8/31/2021$33.00Equal-Weight
    Morgan Stanley
    More analyst ratings

    $ADGI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Invivyd to Participate at Cowen's 43rd Annual Healthcare Conference

      WALTHAM, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD) a clinical-stage biopharmaceutical company on a mission to protect humanity from serious viral respiratory diseases, today announced David Hering, chief executive officer of Invivyd, is scheduled to present at Cowen's 43rd Annual Healthcare Conference on Monday, March 6, 2023 at 2:10 p.m. ET. A live webcast of the presentation will be available in the investor section of the company's website at investors.invivyd.com and will be archived for 90 days following the presentation. About Invivyd(NASDAQ:IVVD)Invivyd, Inc., formerly Adagio Therapeutics (NASDAQ:ADGI), is a biopharmaceutical company on a mission to prot

      2/28/23 7:00:00 AM ET
      $IVVD
      $ADGI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Invivyd Announces Changes to Executive Team

      WALTHAM, Mass., Feb. 03, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD), a clinical stage biopharmaceutical company on a mission to protect humanity from serious infectious diseases, today announced that Laura Walker, Ph.D., the company's chief scientific officer and co-founder, decided to leave the company to pursue other opportunities. The management team has initiated a search process to identify her replacement. Until a permanent successor is named, Invivyd team member Lukas Dillinger, Ph.D., has been appointed as interim Head of Discovery and Pre-Clinical. "On behalf of the company, I extend my gratitude and thanks for Laura's scientific passion and contributions that led to

      2/3/23 7:30:00 AM ET
      $IVVD
      $ADGI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Invivyd Presented Joint Industry Rationale on Potential Expedited Development Pathways for Monoclonal Antibodies at FDA-EMA Workshop

      WALTHAM, Mass., Dec. 19, 2022 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD), a clinical-stage biopharmaceutical company on a mission to protect humanity from serious viral respiratory diseases, was invited to participate in an FDA-EMA workshop on SARS-CoV-2 monoclonal antibodies held on December 15, 2022. Invivyd's chief scientific officer, Laura Walker, Ph.D., alongside Eli Lilly and Company and Regeneron Pharmaceuticals, Inc., presented a joint industry approach for anti-spike monoclonal antibody development to keep pace with SARS-CoV-2 variants. The meeting featured presentations by scientists, clinicians, regulators, and industry representatives to discuss alternative strategies to s

      12/19/22 7:00:00 AM ET
      $ADGI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ADGI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Dabora Rebecca

      4 - Invivyd, Inc. (0001832038) (Issuer)

      12/16/22 5:20:29 PM ET
      $ADGI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Andersen Jill

      4 - Invivyd, Inc. (0001832038) (Issuer)

      12/16/22 5:16:35 PM ET
      $ADGI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Schmidt Peter

      4 - Invivyd, Inc. (0001832038) (Issuer)

      12/16/22 5:14:31 PM ET
      $ADGI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ADGI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Adagio Therapeutics downgraded by Morgan Stanley with a new price target

      Morgan Stanley downgraded Adagio Therapeutics from Equal-Weight to Underweight and set a new price target of $6.00 from $11.00 previously

      1/6/22 8:13:15 AM ET
      $ADGI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Adagio Therapeutics downgraded by Morgan Stanley

      Morgan Stanley downgraded Adagio Therapeutics from Overweight to Underweight

      1/6/22 7:59:18 AM ET
      $ADGI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Adagio Therapeutics downgraded by Jefferies with a new price target

      Jefferies downgraded Adagio Therapeutics from Buy to Hold and set a new price target of $10.00 from $46.00 previously

      12/22/21 5:36:31 AM ET
      $ADGI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ADGI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Adagio Therapeutics Inc. (Amendment)

      SC 13D/A - Adagio Therapeutics, Inc. (0001832038) (Subject)

      8/19/22 5:22:28 PM ET
      $ADGI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Adagio Therapeutics Inc. (Amendment)

      SC 13D/A - Adagio Therapeutics, Inc. (0001832038) (Subject)

      7/5/22 8:11:01 AM ET
      $ADGI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Adagio Therapeutics Inc. (Amendment)

      SC 13D/A - Adagio Therapeutics, Inc. (0001832038) (Subject)

      6/24/22 5:10:52 PM ET
      $ADGI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ADGI
    SEC Filings

    See more
    • Adagio Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Invivyd, Inc. (0001832038) (Filer)

      1/9/23 7:11:01 AM ET
      $ADGI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Adagio Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits

      8-K - Invivyd, Inc. (0001832038) (Filer)

      12/6/22 4:28:56 PM ET
      $ADGI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form D filed by Adagio Therapeutics Inc.

      D - Invivyd, Inc. (0001832038) (Filer)

      11/29/22 5:16:38 PM ET
      $ADGI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ADGI
    Leadership Updates

    Live Leadership Updates

    See more
    • Invivyd Appoints Jeremy Gowler as Chief Operating and Commercial Officer, Promotes Pete Schmidt, M.D., to Chief Medical Officer

      WALTHAM, Mass., Dec. 06, 2022 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD), a clinical-stage biopharmaceutical company on a mission to protect humanity from serious viral respiratory diseases, today announced the appointment of Jeremy Gowler as chief operating and commercial officer, effective December 16, 2022, and the promotion of Pete Schmidt, M.D. to chief medical officer, effective immediately. In his new role Mr. Gowler will oversee operations and commercial activities for the company. Dr. Schmidt will be responsible for overseeing all medical, clinical development and regulatory activities at Invivyd. Dr. Ellie Hershberger, Invivyd's chief development officer, is departing f

      12/6/22 4:01:00 PM ET
      $ADGI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Invivyd Announces the Appointment of Christine Lindenboom to Board of Directors

      WALTHAM, Mass., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD), a clinical-stage biopharmaceutical company on a mission to protect humanity from serious viral respiratory diseases, today announced the appointment of Christine Lindenboom, senior vice president investor relations & corporate communications at Alnylam Pharmaceuticals, Inc., to its board of directors. In addition, Redonda Miller, M.D., M.B.A., president of The Johns Hopkins Hospital, has stepped down from her position on the board. "We are excited to welcome Christine to our board of directors where her business acumen and deep knowledge of the biopharmaceutical industry will round out and enhance our current b

      10/24/22 4:01:00 PM ET
      $ADGI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Invivyd Appoints Fred Driscoll as Interim Chief Financial Officer and Announces Resource Reallocation to Maximize Integrated Discovery Platform

      WALTHAM, Mass., Oct. 13, 2022 (GLOBE NEWSWIRE) -- Invivyd, (NASDAQ:IVVD) a clinical-stage biopharmaceutical company on a mission to protect humanity from serious viral respiratory diseases, today announced the appointment of Fred Driscoll as interim CFO as well as headcount changes to align resources to its key programs. The changes are designed to improve capital efficiency by reallocating resources to programs and functions to support our key activities on an accelerated timeline. As part of the resource realignment, the company is building out additional discovery and early development positions and has eliminated several corporate and commercial positions, among others, to execute effi

      10/13/22 4:01:00 PM ET
      $ADGI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ADGI
    Financials

    Live finance-specific insights

    See more
    • Invivyd Reports Third Quarter 2022 Financial Results and Business Highlights

      Novel monoclonal antibody combination candidate (NVD200) on track to advance into clinical trials in Q1 2023 $419 million in cash, cash equivalents and marketable securities expected to support operating runway into Q2 2024 Conference call scheduled for Thursday, November 10th at 4:30 p.m. ET WALTHAM, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD) a clinical-stage biopharmaceutical company on a mission to protect humanity from serious viral respiratory diseases, today announced financial results and business highlights for the third quarter ended September 30, 2022. "It has been a productive quarter starting with a corporate rebrand emphasizing our commitment to e

      11/10/22 4:01:00 PM ET
      $ADGI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Invivyd to Host Conference Call on November 10 to Discuss Third Quarter 2022 Financial Results and Recent Business Highlights

      WALTHAM, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD) a clinical-stage biopharmaceutical company on a mission to protect humanity from serious viral respiratory diseases, today announced that it will host a conference call on Thursday, November 10, 2022, at 4:30 p.m. ET to discuss its financial results for the third quarter ended September 30, 2022, and recent business highlights. Listeners can register for the webcast via this link. Analysts wishing to participate in the question and answer session should use this link. A replay of the webcast will be available via the company's investor website approximately two hours after the call's conclusion. Those who plan o

      11/2/22 7:00:00 AM ET
      $ADGI
      Biotechnology: Pharmaceutical Preparations
      Health Care